Generic weight-loss drugs could arrive in Canada within months as patents expire

In Toronto, at Dr. David Macklin's weight management clinic, a new word has begun appearing in patient conversations with the same frequency as the name Ozempic itself: generics. For years, Novo Nordisk held an iron grip on the market for semaglutide, the active ingredient in its blockbuster drugs Ozempic and Wegovy. That monopoly kept prices steep—a month's supply ran between $300 and $400, sometimes higher depending on dosage. But in January, the company's patent expired in Canada, and with it came the prospect of cheaper alternatives that could reshape who gets access to these medications and how they're perceived.

The timing matters urgently. Right now, nine generic versions of semaglutide are under review by Health Canada, with the agency targeting a 180-day approval window. Experts estimate generics could be available by summer or early fall. In India, where pharmaceutical companies secured early approval the moment patents lapsed, generics are already selling for as little as $19 Canadian per month, with analysts predicting around 50 versions could flood that market within months. Those Indian drugs will still need to clear Health Canada's review process before reaching Canadian shelves, but the trajectory is clear: the era of expensive, single-source weight-loss medication is ending.

For patients like Sarah Brooks, that shift cannot come fast enough. She started taking Ozempic in 2023 to manage her weight and what she calls "food noise"—the constant mental chatter about food that had dominated her thinking. The drug worked in ways nothing else had; she felt genuinely full after eating for perhaps the first time in her life. Then, in late 2024, she lost her job and with it her health benefits. She stopped taking the medication. The weight returned, as it almost always does when patients discontinue semaglutides. Now employed again with coverage that picks up part of the cost, Brooks is back on Wegovy, but her benefits allow only $2,000 annually for discretionary medications. At current prices, that covers a few months. She worries about what happens when that runs out—whether she'll have to skip doses or abandon the medication entirely, watching the weight creep back on. "I hope it doesn't get to that," she said. "It just makes life easier."

Brooks's situation is not unusual. Dr. Nav Persaud, a staff physician at St. Michael's Hospital in Toronto and Canada Research Chair in Health Justice, sees patients daily who face impossible arithmetic: medication or groceries. Those with insurance often cannot afford the co-payments. Those without coverage almost always have to reduce their dose or stop entirely. The result is predictable and demoralizing. Patients regain weight, feel they wasted money, and wish they had never learned about the drug at all. Persaud argues the federal government could have issued a compulsory licence years ago, allowing a third party to manufacture semaglutide before patents expired, but that moment has passed. Now the question is what generics will cost. Mina Tadrous, an associate professor at the University of Toronto's Leslie Dan Faculty of Pharmacy, estimates that once enough generic competitors enter the market, prices could fall to around $100 monthly or less, depending on dosage. "I think it'll be a big turning point," he said.

Beyond individual access, doctors see broader implications. Dr. Macklin notes that obesity remains heavily stigmatized—viewed as a "disease of choice," a failure of willpower rather than a medical condition. When patients experience how effectively semaglutides work where diet and exercise have failed, something shifts in their understanding. They recognize the problem as biological, not moral. Wider access through generics could amplify that realization across the population, potentially eroding the shame that has long surrounded weight management. Macklin also points to the economic case: Obesity Canada estimates the annual cost of untreated obesity at $27.6 billion. Cheaper medications that keep people on treatment could reduce that burden substantially.

But the arrival of generics also raises concerns. Dr. Iris Gorfinkel, a family medicine practitioner in Toronto, notes that GLP-1 drugs are now requested daily by patients who don't meet clinical criteria for their use—particularly women seeking to lose 10 or 15 pounds for cosmetic reasons. Generics will make these drugs more accessible not only to those who need them but to those who want them for reasons outside approved use. The medications are not without side effects: nausea, vomiting, diarrhea, and stomach pain are common, and many patients discontinue use long-term. Meanwhile, unauthorized online services already dispense these drugs to people who misrepresent their health status. Health Canada warned about counterfeit versions earlier this year. Persaud suggests, somewhat counterintuitively, that lower prices might actually reduce the appeal of these grey-market services—if the medication were affordable through legitimate channels, the incentive to seek it elsewhere would diminish.

What comes next depends partly on how quickly Health Canada moves and how aggressively generic manufacturers enter the Canadian market. The regulatory machinery is in motion. The question now is whether the price drop will be steep enough and fast enough to reach the patients who need it most, or whether cost will remain a barrier even after patents expire.